Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus

International Journal of Obesity Supplements volume 4, pages S9–S13 (2014)Cite this article

Subjects

Abstract

Glucagon-like peptide-1 (GLP-1) is a gastrointestinal hormone secreted from L cells in the distal small intestine and proximal colon after a meal that acts as an incretin to augment the insulin response, while also inhibiting glucagon and slowing gastric emptying. These characteristics of GLP-1, as well as its ability to reduce islet beta cell apoptosis and expand beta cell mass and its cardioprotective and neuroprotective effects, provide a broad spectrum of actions potentially useful for the management of type-2 diabetes mellitus. GLP-1 also has the added advantage of having its incretin effects dependent on the level of serum glucose, only acting in the presence of hyperglycaemia, and thereby preventing hypoglycemic responses. Although natural GLP-1 has a very short half-life, limiting its therapeutic usefulness, a variety of analogues and formulations have been developed to provide extended actions and to limit side effects. However, all of these peptides require parenteral administration. Potentially orally active small-molecule agonists acting at the GLP-1 receptor are also being developed, but have not yet been approved for clinical use. Recent insights into the molecular nature of the class B G-protein-coupled GLP-1 receptor has provided insights into the modes of binding these types of ligands, as well as providing opportunities for rational enhancement. The advantages and disadvantages of each of these agents and their possible clinical utility will be explored.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Hu FB . Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 2011; 34: 1249–1257.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Creutzfeldt W . The incretin concept today. Diabetologia 1979; 16: 75–85.

    Article  CAS  PubMed  Google Scholar 

  3. Elrick H, Stimmler L, Hlad Jr CJ, Arai Y . Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964; 24: 1076–1082.

    Article  CAS  PubMed  Google Scholar 

  4. Nauck M, Stockmann F, Ebert R, Creutzfeldt W . Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46–52.

    Article  CAS  PubMed  Google Scholar 

  5. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O . Structure-activity studies of glucagon-like peptide-1. J Biol Chem 1994; 269: 6275–6278.

    CAS  PubMed  Google Scholar 

  6. Neidigh JW, Fesinmeyer RM, Prickett KS, Andersen NH . Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry 2001; 40: 13188–13200.

    Article  CAS  PubMed  Google Scholar 

  7. Hoare SR . Mechanisms of peptide and nonpeptide ligand binding to class B G-protein-coupled receptors. Drug Discov Today 2005; 10: 417–427.

    Article  CAS  PubMed  Google Scholar 

  8. Dong M, Lam PC, Pinon DI, Hosohata K, Orry A, Sexton PM et al. Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore. J Biol Chem 2011; 286: 23888–23899.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. White JW, Saunders GF . Structure of the human glucagon gene. Nucleic Acids Res 1986; 14: 4719–4730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Mortensen K, Christensen LL, Holst JJ, Orskov C . GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003; 114: 189–196.

    Article  CAS  PubMed  Google Scholar 

  11. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B et al. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 2003; 55: 167–194.

    Article  CAS  PubMed  Google Scholar 

  12. Shoichet BK, Kobilka BK . Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol Sci 2012; 33: 268–272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT . Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci 2009; 34: 303–310.

    Article  CAS  PubMed  Google Scholar 

  14. Lisenbee CS, Dong M, Miller LJ . Paired cysteine mutagenesis to establish the pattern of disulfide bonds in the functional intact secretin receptor. J Biol Chem 2005; 280: 12330–12338.

    Article  CAS  PubMed  Google Scholar 

  15. Miras AD, Jackson RN, Jackson SN, Goldstone AP, Olbers T, Hackenberg T et al. Gastric bypass surgery for obesity decreases the reward value of a sweet-fat stimulus as assessed in a progressive ratio task. Am J Clin Nutr 2012; 96: 467–473.

    Article  CAS  PubMed  Google Scholar 

  16. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP . Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267: 7402–7405.

    CAS  PubMed  Google Scholar 

  17. Donnelly D . The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol 2012; 166: 27–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083–1091.

    Article  CAS  PubMed  Google Scholar 

  19. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 2007; 29: 139–153.

    Article  CAS  PubMed  Google Scholar 

  20. Christensen M, Knop FK, Holst JJ, Vilsboll T . Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009; 12: 503–513.

    CAS  PubMed  Google Scholar 

  21. Knudsen LB . Liraglutide: the therapeutic promise from animal models. Int J Clin Pract Suppl 2010; 64: 4–11.

    Article  CAS  Google Scholar 

  22. Nauck MA, Meier JJ . Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005; 128: 135–148.

    Article  CAS  PubMed  Google Scholar 

  23. Meier JJ . GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728–742.

    Article  CAS  PubMed  Google Scholar 

  24. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564–2571.

    Article  CAS  PubMed  Google Scholar 

  25. Baggio LL, Huang Q, Brown TJ, Drucker DJ . Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127: 546–558.

    Article  CAS  PubMed  Google Scholar 

  26. Chen D, Liao J, Li N, Zhou C, Liu Q, Wang G et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proc Natl Acad Sci USA 2007; 104: 943–948.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Irwin N, Flatt PR, Patterson S, Green BD . Insulin-releasing and metabolic effects of small molecule GLP-1 receptor agonist 6,7-dichloro-2-methylsulfonyl-3-N-tert-butylaminoquinoxaline. Eur J Pharmacol 2010; 628: 268–273.

    Article  CAS  PubMed  Google Scholar 

  28. Knudsen LB, Kiel D, Teng M, Behrens C, Bhumralkar D, Kodra JT et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA 2007; 104: 937–942.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sloop KW, Willard FS, Brenner MB, Ficorilli J, Valasek K, Showalter AD et al. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 2010; 59: 3099–3107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Su H, He M, Li H, Liu Q, Wang J, Wang Y et al. Boc5, a non-peptidic glucagon-like Peptide-1 receptor agonist, invokes sustained glycemic control and weight loss in diabetic mice. PLoS One 2008; 3: e2892.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Willard FS, Bueno AB, Sloop KW . Small molecule drug discovery at the glucagon-like peptide-1 receptor. Exp Diabetes Res 2012; 2012: 709893.

    PubMed  PubMed Central  Google Scholar 

  32. Koole C, Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM . Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation. J Biol Chem 2012; 287: 3642–3658.

    Article  CAS  PubMed  Google Scholar 

  33. Koole C, Wootten D, Simms J, Savage EE, Miller LJ, Christopoulos A et al. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. J Biol Chem 2012; 287: 3659–3673.

    Article  CAS  PubMed  Google Scholar 

  34. Koole C, Wootten D, Simms J, Valant C, Sridhar R, Woodman OL et al. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Mol Pharmacol 2010; 78: 456–465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Harikumar KG, Wootten D, Pinon DI, Koole C, Ball AM, Furness SGB et al. Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signalling but does not affect small molecule allostery. Proc Natl Acad Sci USA 2012; 109: 18607–18612.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Gao F, Harikumar KG, Dong M, Lam PC, Sexton PM, Christopoulos A et al. Functional importance of a structurally distinct homodimeric complex of the family B G protein- coupled secretin receptor. Mol Pharmacol 2009; 76: 264–274.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from the National Institutes of Health (DK046577). PS has received an NHMRC Program grant (#519461) and an NHMRC Project grant (#1002180).

Author information

Authors and Affiliations

  1. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Scottsdale, AZ, USA

    L J Miller, M Dong & K G Harikumar

  2. Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Drug Discovery Biology, Monash University, Parkville, Victoria, Australia,

    P M Sexton

Authors
  1. L J Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P M Sexton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K G Harikumar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L J Miller.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

This article is published as part of a supplement sponsored by the Université Laval's Research Chair in Obesity in an effort to inform the public on the causes, consequences, treatments, and prevention of obesity.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miller, L., Sexton, P., Dong, M. et al. The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus. Int J Obes Supp 4 (Suppl 1), S9–S13 (2014). https://doi.org/10.1038/ijosup.2014.4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijosup.2014.4

Keywords

Search

Advanced search

Quick links